CompoundBrief

Weekly roundup

This Week in Peptide Research: Oct 26, 2026

Published October 26, 2026 · 3 min read

Scope: All compounds mentioned are investigational or unapproved unless stated. Summary for research and education only. Items marked "sponsor announcement" are company-reported and not yet peer-reviewed. Compound Brief is published by the team behind DAAVY Research.

1. Kennedy: "a regulated marketplace" for peptides

On October 20, HHS Secretary Robert F. Kennedy Jr. said in a Fox News interview that "Americans are going to be buying these anyway" and that the goal is "a regulated marketplace, so that what they're getting is what they claim to be." The interim compounding policy he was asked about was sent to the White House for review on October 14 or 15 (sources differ) and its text is not public. Source: Reuters via GV Wire. Background: our explainer.

2. Citizen petition asks FDA to block peptide compounding

On October 21 the Partnership for Safe Medicines announced a citizen petition asking FDA to block compounding of the seven substances reviewed by its July advisory committee (the committee voted to recommend six). The group alleges committee composition violated federal ethics and advisory-committee law and says FDA scientists found "extremely limited safety data." These are the petitioner's claims; FDA had not responded in coverage we found. Source: PSM press release. More: full article.

3. Survodutide SYNCHRONIZE-2 (sponsor announcement)

Boehringer Ingelheim reported on October 1 that survodutide, a glucagon/GLP-1 dual agonist, produced up to 13.1% weight loss versus 3.1% with placebo at 76 weeks (efficacy estimand) in 755 adults with obesity or overweight and type 2 diabetes. HbA1c fell by up to 1.21 points versus 0.03. Discontinuation because of gastrointestinal adverse events was 18% with survodutide versus 1.2% with placebo, mostly during dose escalation. The release gives no treatment-regimen figures. Source: Boehringer Ingelheim.

4. Petrelintide ZUPREME-2 (sponsor announcement)

Zealand Pharma reported on October 7 that the amylin analog petrelintide met its primary endpoint in a 220-person phase 2b trial in adults with overweight or obesity and type 2 diabetes. At week 28, mean weight loss was up to 9.2% (efficacy estimand; range 7.4% to 9.2% across three doses) versus 2.0% with placebo. HbA1c fell by up to 0.65% versus a 0.23% rise with placebo. GI-related discontinuations were 1.9% versus 1.7%. The trial is short (28 weeks) and the release gives no dose amounts. Source: Zealand Pharma.

5. CagriSema subgroup analysis in women (company statement)

Novo Nordisk said an unplanned analysis of REDEFINE 1 (68 weeks) found about 25% average weight loss in women versus about 3% with placebo: 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women (placebo 2.1%, 1.7%, 2.6%). Subgroup sizes were not reported, and the overall trial result was reported as 20.4%. Subgroup analyses that were not prespecified are hypothesis-generating at best. Source: pharmaphorum.

Reading across items 3 to 5: these are different trials of different molecules in different populations, so their weight-loss numbers cannot be ranked against each other. See How to Read a Clinical Trial Result.

← Back to all articles